ITGAX and neoplasm: Co-immunostaining of CD206, CD11c and F4/80 showed that the percentages of macrophages expressed CD206 in tumor tissue of CHA-treated mice were fewer than the control group (26.6% in 20 mg/kg group; 8.33% in 40 mg/kg group Vs 63.8% in control group) (Fig. 5E,F).